Side-by-side · Research reference

TB-500vsTesofensine

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed8/46 cited

BPhase 3Draft10/40 cited

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

Tesofensine

SNDRI · Phase 3 obesity candidate

0.25–0.5 mgDaily doseAstrup 2008

9.2 kgWeight ↓ (24 wk)Astrup 2008

Phase 3Evidence levelAstrup 2008

Oral · Once daily morning

01Mechanism of Action

Parameter

TB-500

Tesofensine

Primary target

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008

Pathway

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008

Downstream effect

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008

Feedback intact?

Endogenous protein at baseline; supplementation amplifies

—

Origin

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008

Antibody development

—

02Dosage Protocols

Parameter

TB-500

Tesofensine

Standard dose

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

0.25–0.5 mg / dayAstrup 2008

Frequency

2× per week (loading); then 1× per week (maintenance)

Once daily, morning

Lower / starter dose

1 mg per injection

0.125 mg / day

Evidence basis

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

Phase 2b + ongoing Phase 3Astrup 2008

Duration

4–8 weeks loading; longer maintenance for chronic injury

24 weeks per studied cycle

Reconstitution

Bacteriostatic water, 1–2 mL per 5 mg vial

—

Timing

Evening or pre-rest preferred (anecdotal)

Morning to avoid sleep disruption

Half-life

~2 hours (estimated; tissue uptake longer)

~9 days (very long)

Form

—

Oral capsule

04Side Effects & Safety

Parameter

TB-500

Tesofensine

Injection site reaction

Mild erythema, transient pain

—

GI symptoms

Rare nausea (anecdotal)

—

Cancer risk

Theoretical via angiogenesis pathway

—

Lethargy / fatigue

Reported anecdotally during loading phase

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid

Contraindicated

Long-term safety

Unknown beyond Phase 2

—

Heart rate / BP

—

Dose-dependent ↑ HR + BPAstrup 2008

Insomnia

—

Dose-related; mitigate with morning timing

Dry mouth

—

Common

Nausea

—

Common

Mood changes

—

Anxiety / agitation possible

Cardiovascular events

—

Phase 3 trial monitoring; not yet FDA-cleared

Absolute Contraindications

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Tesofensine

·Pregnancy / breastfeeding
·Severe cardiovascular disease
·Concurrent MAOI use

Relative Contraindications

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

Tesofensine

·Hypertension
·Anxiety disorder
·Insomnia

05Administration Protocol

Parameter

TB-500

Tesofensine

1. Reconstitution

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

Oral capsule (investigational; not commercial).

2. Injection site

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

Swallow whole with water, morning only.

3. Timing

Evening or pre-sleep is most common anecdotal timing.

Morning to mitigate insomnia. Do not dose evening.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

Room temp ≤25 °C, dry place.

5. Needle

27–31G, 4–8 mm insulin syringe.

Monitor BP + HR + mood. Avoid stimulants + MAOIs.

06Stack Synergy

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair

Tesofensine

— no documented stacks